NCT05718921View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 8, 2023

Primary Completion Date

August 14, 2023

Study Completion Date

December 14, 2023

Conditions
Atopic DermatitisPsoriasis
Interventions
DRUG

YR001 Dose A on low body surface area

Part A: Single topical dose

DRUG

YR001 Dose A on middle body surface area

Part A: Single topical dose

DRUG

YR001 Dose A on high body surface area

Part A: Single topical dose

DRUG

YR001 Dose B on low body surface area

Part A: Single topical dose

DRUG

YR001 Dose B on middle body surface area

Part A: Single topical dose

DRUG

YR001 Dose B on high body surface area

Part A: Single topical dose

DRUG

Placebo on low body surface area

Part A: Single topical dose

DRUG

Placebo on middle body surface area

Part A: Single topical dose

DRUG

Placebo on high body surface area

Part A: Single topical dose

DRUG

YR001 Dose A on high body surface area twice daily

Part B: Multiple topical dose

DRUG

YR001 Dose B on high body surface area twice daily

Part B: Multiple topical dose

DRUG

Placebo on high body surface area twice daily

Part B: Multiple topical dose

Trial Locations (1)

92024

California Dermatology & Clinical Research Institute, Encinitas

All Listed Sponsors
lead

Hangzhou Yirui Pharmaceutical Technology Co., Ltd

INDUSTRY